Website: N/A
Stock Symbol: NASDAQ: XNPT
Market Value: N/A (in millions)
We are a biopharmaceutical company focused on developing a portfolio of
internally discovered product candidates that utilize the body’s natural
nutrient transporter mechanisms to improve the therapeutic benefits of drugs. We
intend to focus our development and commercialization efforts on potential
treatments of central nervous system, or CNS, disorders. Our most advanced
product candidate, XP13512, is currently being evaluated for the treatment of
restless legs syndrome, or RLS, in a Phase 3 clinical program in the United
States and has also successfully completed a Phase 2a clinical trial for the
management of post-herpetic neuralgia, or PHN, in the United States. One of our
partners, Astellas Pharma Inc., is evaluating this product candidate in two
separate Phase 2 clinical trials in Japan for the treatment of painful diabetic
neuropathy, or PDN, and RLS.